Literature DB >> 32622305

A novel pathophysiological classification of silicosis models provides some new insights into the progression of the disease.

Zhujie Cao1, Meiyue Song2, Ying Liu1, Junling Pang1, Zhaoguo Li3, Xianmei Qi1, Ting Shu1, Baicun Li1, Dong Wei4, Jingyu Chen4, Bolun Li1, Jing Wang5, Chen Wang6.   

Abstract

Silicosis is caused by massive inhalation of silica-based particles, which leads to pulmonary inflammation, pulmonary fibrosis and lung dysfunction. Currently, the pathophysiological process of silicosis has not been well studied. Here, we defined the progression of silicosis as four stages by unsupervised clustering analysis: normal stage, inflammatory stage, progressive stage and fibrotic stage. Specifically, in normal stage, the lung function was normal, and no inflammation or fibrosis was detected in the lung tissue. Inflammatory stage showed a remarkable pulmonary inflammation but mild fibrosis and lung dysfunction. In progressive stage, significant lung dysfunction was observed, while pulmonary inflammation and fibrosis continued to deteriorate. Fibrotic stage revealed the most severe pulmonary fibrosis and lung dysfunction but no significant deterioration in inflammation. Since the common features were founded in both silicosis patients and rodents, we speculated that the pathophysiological processes of silicosis in patients might be similar to the rodents. Collectively, our new classification identified the process of silicosis, clarified the pathophysiological features of each stage, and provided some new insights for the progression of the disease.
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Classification; Lung function; Progression; Pulmonary fibrosis; Pulmonary inflammation; Silicosis

Year:  2020        PMID: 32622305     DOI: 10.1016/j.ecoenv.2020.110834

Source DB:  PubMed          Journal:  Ecotoxicol Environ Saf        ISSN: 0147-6513            Impact factor:   6.291


  10 in total

1.  Minute Cellular Nodules as Early Lesions in Rats with Silica Exposure via Inhalation.

Authors:  Yaqian Li; Fuyu Jin; Tian Li; Xinyu Yang; Wenchen Cai; Shifeng Li; Xuemin Gao; Na Mao; Heliang Liu; Hong Xu; Fang Yang
Journal:  Vet Sci       Date:  2022-05-25

2.  A Novel N-Arylpyridone Compound Alleviates the Inflammatory and Fibrotic Reaction of Silicosis by Inhibiting the ASK1-p38 Pathway and Regulating Macrophage Polarization.

Authors:  Mingming Fan; Huijuan Xiao; Dingyun Song; Lili Zhu; Jie Zhang; Xinran Zhang; Jing Wang; Huaping Dai; Chen Wang
Journal:  Front Pharmacol       Date:  2022-03-23       Impact factor: 5.810

3.  The significance of serum S100 calcium-binding protein A4 in silicosis.

Authors:  Jing Zhang; Cuifang Yuan; Enhong Li; Yiming Guo; Jie Cui; Heliang Liu; Xiaohui Hao; Lingli Guo
Journal:  BMC Pulm Med       Date:  2022-04-04       Impact factor: 3.317

4.  Tetrandrine alleviates silicosis by inhibiting canonical and non-canonical NLRP3 inflammasome activation in lung macrophages.

Authors:  Mei-Yue Song; Jia-Xin Wang; You-Liang Sun; Zhi-Fa Han; Yi-Tian Zhou; Ying Liu; Tian-Hui Fan; Zhao-Guo Li; Xian-Mei Qi; Ya Luo; Pei-Ran Yang; Bai-Cun Li; Xin-Ri Zhang; Jing Wang; Chen Wang
Journal:  Acta Pharmacol Sin       Date:  2021-08-20       Impact factor: 6.150

5.  Every road leads to Rome: therapeutic effect and mechanism of the extracellular vesicles of human embryonic stem cell-derived immune and matrix regulatory cells administered to mouse models of pulmonary fibrosis through different routes.

Authors:  Shengnan Yang; Peipei Liu; Tingting Gao; Dingyun Song; Xinyu Zhao; Yupeng Li; Jun Wu; Liu Wang; Zai Wang; Jie Hao; Chen Wang; Huaping Dai
Journal:  Stem Cell Res Ther       Date:  2022-04-12       Impact factor: 6.832

6.  Inhibition of gasdermin D-dependent pyroptosis attenuates the progression of silica-induced pulmonary inflammation and fibrosis.

Authors:  Meiyue Song; Jiaxin Wang; Youliang Sun; Junling Pang; Xiaona Li; Yuan Liu; Yitian Zhou; Peiran Yang; Tianhui Fan; Ying Liu; Zhaoguo Li; Xianmei Qi; Baicun Li; Xinri Zhang; Jing Wang; Chen Wang
Journal:  Acta Pharm Sin B       Date:  2021-10-15       Impact factor: 14.903

7.  Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis: a multi-omics study with drug exploration.

Authors:  Mingyao Wang; Zhe Zhang; Jiangfeng Liu; Meiyue Song; Tiantian Zhang; Yiling Chen; Huiyuan Hu; Peiran Yang; Bolun Li; Xiaomin Song; Junling Pang; Yanjiang Xing; Zhujie Cao; Wenjun Guo; Hao Yang; Jing Wang; Juntao Yang; Chen Wang
Journal:  Signal Transduct Target Ther       Date:  2022-05-13

8.  Impaired interferon-γ signaling promotes the development of silicosis.

Authors:  Zhouyangfan Peng; Mingwu Duan; Yiting Tang; Jianfeng Wu; Kai Zhao; Yanjun Zhong; Zhihui He; Jie Meng; Fangping Chen; Xianzhong Xiao; Haichao Wang; Timothy R Billiar; Ben Lu; Fang Liang
Journal:  iScience       Date:  2022-06-19

9.  RAB20 deficiency promotes the development of silicosis via NLRP3 inflammasome.

Authors:  Zhouyangfan Peng; Mingwu Duan; Kai Zhao; Yiting Tang; Fang Liang
Journal:  Front Immunol       Date:  2022-09-05       Impact factor: 8.786

10.  Pirfenidone ameliorates silica-induced lung inflammation and fibrosis in mice by inhibiting the secretion of interleukin-17A.

Authors:  Zhu-Jie Cao; Ying Liu; Zhe Zhang; Pei-Ran Yang; Zhao-Guo Li; Mei-Yue Song; Xian-Mei Qi; Zhi-Fa Han; Jun-Ling Pang; Bai-Cun Li; Xin-Ri Zhang; Hua-Ping Dai; Jing Wang; Chen Wang
Journal:  Acta Pharmacol Sin       Date:  2021-07-27       Impact factor: 6.150

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.